Navigation Links
New potential drug target for the treatment of atherosclerosis
Date:3/4/2008

LA JOLLA, CA A nuclear receptor protein, known for controlling the ability of cells to burn fat, also exerts powerful anti-inflammatory effects in arteries, suppressing atherosclerosis in mice prone to developing the harmful plaques, according to new research by scientists at the Salk Institute for Biological Studies and the Harvard School of Public Health.

Their findings, reported in this weeks online edition of the Proceedings of the National Academy of Sciences, offer a new and specific target for the development of drugs that specifically treat cardiovascular complications associated with metabolic syndrome.

Heart disease is like a ticking clockit is progressive, relentlessly marching forward accelerated by a mix of high fat diets, inflammation and high blood pressure. We show that PPAR delta offers a kind of genetic shortcut around each of these medical roadblocks, says Howard Hughes Medical Investigator Ronald M. Evans, Ph.D., a professor in the Salk Institutes Gene Expression Laboratory, who co-directed the study with Chih-Hao Lee, a professor in the Department of Genetics and Complex Diseases at the Harvard School of Public Health.

Most people believe cholesterol plays a predominant role in atherosclerosis. Our study suggests that targeting inflammation at lesion sites is just as important, adds Lee.

Like the Yin and Yang of fat metabolism, PPAR delta the focus of the current study and its counterpart PPAR gamma control the storage and burning of fat. PPAR gamma is in charge of storing surplus glucose as fat. When PPAR gamma is stimulated by a drug the bodys response to insulin improves, lowering levels of circulating glucose. Its sibling gene switch, PPAR delta, controls the ability of cells to burn fat. Activating PPAR delta revs up the fat-burning capacity of adipose tissue and muscle, dramatically lowers overall body weight, increases HDL (the good cholesterol), reduces circulating triglycerides, and improves hyperglycemia.

Cardiovascular disease is a leading cause of death in patients with metabolic syndrome, a clustering of obesity-related disorders including insulin resistance, hypertension, and dyslipidemia, says postdoctoral researcher and first author Grant D. Barish, M.D. Since PPAR delta plays a key role in fat metabolism and PPAR delta drugs can protect against obesity, we wanted to know whether activating PPAR delta would protect against atherosclerosis.

Atherosclerosis or hardening of the arteries" is a chronic disease in which high cholesterol levels coupled with inflammation lead to the build-up of fatty deposits, called plaque, on the inner walls of arteries. Eventually these plaques can limit blood flow, leading to angina, or they may rupture, resulting in blood clots that block arteries and cause heart attacks or strokes.

When the researchers fed an experimental drug that turns on PPAR delta to genetically altered mice that develop the characteristic plaques at an early age, especially when placed on a high-fat diet, mice developed 2530 percent fewer plaques. Further studies revealed that PPAR delta not only raises HDL levels but also suppresses the inflammatory response in the artery, dramatically slowing down lesion progression.

Barish and Evans also contributed to a related study, which was led by researchers at the University of California, Los Angeles and published in the same issue of PNAS. Using a different mouse model to mimic the development of atherosclerosis, the UCLA researchers detected an even more pronounced anti-inflammatory effect that slashed the number of aortic lesions by up to 70 percent.

While Barish, a clinically trained endocrinologist, cautions that extrapolating from mice to humans is inherently fraught with complications, he believes that drugs switching on PPAR delta have the potential to protect against obesity, insulin resistance and their associated cardiovascular risks.

The discovery that any orally active compound can delay the progression of heart disease is rare, and considering the importance of the problem, we are hopeful that this work can be quickly carried into the clinic, says Evans.


'/>"/>

Contact: Gina Kirchweger
kirchweger@salk.edu
858-453-410-01340
Salk Institute
Source:Eurekalert  

Related medicine news :

1. Large source of nitrate, a potential water contaminant, found in near-surface desert soils
2. Weill Cornell team identifies potential new drug targets against hormone-dependent breast cancer
3. Alimera Sciences Signs Second Agreement With Emory University for Potential Treatments Using New Class of Antioxidants
4. Researcher of the University of Navarra discovered potential antidepressant compounds
5. Scientists using laser light to detect potential diseases via breath samples, says new study
6. ASAM Calls for Care in the Use of, and the Prescribing of, Potentially Addictive Substances
7. Growing markets bring potential for rubber and oilseed crops
8. Heating Plastic Bottles Releases Potentially Harmful Chemical
9. Hot liquids release potentially harmful chemicals in polycarbonate plastic bottles
10. New nanotube findings by Stanford researchers give boost to potential biomedical applications
11. Battling potential disease outbreaks online
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New potential drug target for the treatment of atherosclerosis
(Date:5/26/2016)... ... May 26, 2016 , ... The Woodlands at John ... a new model of care for living and healing, celebrated its grand opening, today. ... in a Real Home provided by Empowered Staff. , “This is an incredibly fulfilling ...
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line of ... New Hampshire at the MadgeTech headquarters. With products sold in more than 100 countries ... agencies, including NASA. , In 2012, NASA strategically set up 17 RHTemp101A ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found rising health care ... of Sun Health Senior Living (SHSL) may not share those same worries ... prescription copays for the year, while holding the line on increasing their contributions, including ...
(Date:5/26/2016)... ... 26, 2016 , ... Leadership of Life Science Logistics (LSL), ... has earned its ISO 13485 certification, indicating the company’s quality control system for ... policies associated with ISO quality standard 13485. , BSI Group America, Inc., ...
(Date:5/26/2016)... Cypress, Texas (PRWEB) , ... May 26, 2016 , ... ... on Friday, May 13 at Blackhorse Golf Club in Cypress. With the help of ... a non-profit that restores, empowers, and renews hope for wounded service members and their ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... According to a new market ... 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application ... Manufacturers, Hospitals/ Clinics) - Forecast to 2021", published by ... for the forecast period of 2016 to 2021. This ... 2021 from USD 117.3 Million in 2016, at a ...
(Date:5/25/2016)... , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... a licensing and co-development agreement with Therawis Diagnostics GmbH to ... will be to develop and market PITX2 as a marker ... other high-risk breast cancer patients. "We are pleased ...
(Date:5/25/2016)... May 25, 2016  According to Kalorama Information, the ... in 2015.  Though these are challenging times in ... for success for companies that remain optimistic and ... new growth prospects medical device companies spend a ... development (R&D) than do companies in other industries.  ...
Breaking Medicine Technology: